This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Epigenetics and Human Disease
joint with 3D Genome: Gene Regulation and Disease
Organizer(s): Cheryl H. Arrowsmith, Anne Schaefer and Mark A. Dawson
Date: March 17 - 21, 2019
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by Cell Research, Incyte Corporation, Novartis Institutes for BioMedical Research and Pfizer Inc.
Summary of Meeting:
Epigenetics is a major mechanism in human health and disease. Data from a range of diseases (cancer, neurological and immunological disorders) have uncovered altered epigenomes arising from mutations, altered expression and/or copy number alterations of numerous epigenetic factors (histones, DNA and chromatin modifying enzymes, reader proteins, chromatin modulators and noncoding RNAs). Genome-wide analyses have illustrated the relationship between altered epigenetic states (e.g., modified DNA, histones and chromatin packaging) and disease onset and progression. Furthermore, both local and long-range nuclear chromatin architecture are increasingly recognized as major contributors to normal and pathologic epigenetic states. This conference, held jointly with a conference on “3D Genome”, will cover the most current knowledge of epigenetic events modulating nuclear function (gene expression regulation, enhancer modulation, domains and structural organization as well as cell division and differentiation), while relating this to normal and disease models. In addition, this conference will highlight the impact that preclinical and clinical epigenetic therapeutics have on multiple diseases including cancer, immunological and neurological disorders. An interdisciplinary panel of speakers including both thought leaders in the field as well as young investigators will survey the latest research results and conceptual understanding of fundamental mechanisms of epigenetic signaling, especially as they relate to regulation of gene expression programs. Presentations and workshops will highlight the latest technologies and methodologies for studying epigenetic states and 3D chromatin architecture in cells, tissues and organisms.
Scholarship Deadline: November 29 2018
Discounted Abstract Deadline: November 29 2018
Abstract Deadline: December 12 2018
Discounted Registration Deadline: January 22 2019
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Cell ResearchIncyte CorporationNovartis Institutes for BioMedical ResearchPfizer Inc.
We gratefully acknowledge additional support from these exhibitors at this conference:
EpiCypherIllumina10x Genomics
We gratefully acknowledge additional support for this conference from:
American Association for Cancer Research (AACR)American Society of Gene & Cell Therapy (ASGCT)Chroma Technology CorporationZymo Research Corporation
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

GlaxoSmithKline
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA236128-01
Funding for this conference was made possible (in part) by 1R13CA236128-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found